Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab
Authors:
- Bernardo StefaniniBSBernardo Stefanini
- Fabio PiscagliaFPFabio Piscaglia
- Fabio MarraFMFabio Marra
- Massimo IavaroneMIMassimo Iavarone
- Caterina VivaldiCVCaterina Vivaldi
- Giuseppe CabibboGCGiuseppe Cabibbo
- Andrea PalloniAPAndrea Palloni
- Tiziana PressianiTPTiziana Pressiani
- Andrea DalbeniADAndrea Dalbeni
- Benedetta StefaniniBSBenedetta Stefanini
- Leonardo StellaLSLeonardo Stella
- Piera FedericoPiera Federico
Open Access
- 26 May 2025
- journal article
- Published by S. Karger AG in Liver Cancer
- Vol. 15 (1) , 10-23
Abstract
Background: Preclinical models have shown that metabolic dysfunction-associated steatotic liver disease (MASLD)-related hepatocellular carcinoma (HCC) may exhibit reduced responsiveness to immunotherapy, especially for intrahepatic lesions due to liver tumor microenvironment. Radiological pattern of progression has been validated in clinical studies as a useful tool for predicting outcomes in HCC undergoing systemic treatments. Aims: The aim of this study was to determine whether MASLD influences the pattern of progression in patients treated with atezolizumab-bevacizumab. Methods: This multicenter, prospective study included patients with unresectable HCC receiving atezolizumab-bevacizumab. Progression patterns were defined as previously proposed. Patients were categorized as either MASLD or controls based on a recent multisocietal Delphi consensus statement. Multivariable models analyzed the risk of specific progression patterns and their impacts on post-progression survival (PPS) and overall survival (OS). A historical cohort treated with sorafenib was also analyzed to determine whether observed patterns were specific for atezolizumab-bevacizumab. Results: Four-hundred twenty patients were included (MASLD: n = 88, 21.0%). Time to progression (TTP) was shorter in MASLD compared to controls, due to an increased risk of intrahepatic growth (IHG – hazard ratio [HR] 1.739, 95% confidence interval [CI] 1.206–2.507, p = 0.003]). Neither etiology nor IHG predicted a different PPS. No differences between etiologies were found in OS. Etiology did not influence the pattern of progression under sorafenib in the historical cohort. Conclusion: IHG was more frequently associated with MASLD-HCC compared to controls, confirming preclinical data and suggesting biological differences between tumors, with potential implications for future research. MASLD should not be seen as a contraindication to immunotherapy.Keywords
This publication has 30 references indexed in Scilit:
- Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trialsLiver International, 2021
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- NASH limits anti-tumour surveillance in immunotherapy-treated HCCNature, 2021
- Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective StudyLiver Cancer, 2021
- Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumabLiver International, 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular CarcinomaLiver Cancer, 2019
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyThe Lancet Oncology, 2018
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial designHepatology, 2013
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009